The recent filings indicated the timeline which stated work on pre IND for RT-AR001 is on going followed by IND application and a update in second half of 2021. Maybe a FDA approval to start trials later this year? As of now there has been no mention to a change in this timeline. On a different but related point Tarus Therapeutics received the FDA approval to start trials on their Adenosine based drug TT-10 a A2AR antagonist for solid tumors. Adenosine based drugs in Cancer Immunotherapy are getting more attention so this can only be a positive for NSPX.
News 
Market Data 
Discover 
